BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Nov. 9, 2015
View Archived Issues
New HIV therapeutics benefit from two decades of research
The FDA approval of Gilead Sciences Inc.'s once-daily, single-tablet regimen branded Genvoya on its Nov. 5 PDUFA date adds another point on the development trajectory graph of antiviral therapies. (See BioWorld Today, Nov.6, 2015.)
Read More
Most me-too drugs start before risk is abated
There can be only one first-in-class drug. Every drug developed after that is a me-too drug in the most basic sense.
Read More
Week in review
Read More
Week in Washington
Read More
Word on the street
Read More
The week's biggest gainers and losers
Read More
BioWorld stock report for public biotechnology companies
Read More
BioWorld Stock Index 2015
Read More
Nasdaq Stock Index 2015
Read More
Money raised by biotech: Jan. 1 - Nov. 5, 2015
Read More
Public financing of biotechnology companies: Commenced trading in October 2015
Read More
Public financing of biotechnology companies: Filed and pending IPOs
Read More
Other financings of public biotechnology companies: October 2015
Read More
2015 top financings of public companies
Read More
2015 top financings of private companies
Read More
Venture capital & other investments in private biotechnology companies: October 2015
Read More
Milestone payments from corporate partners: October 2015
Read More
Money raised by biotech in 2015 vs. 2014
Read More